Dihydroartemisinin regulates the immune system by promotion of CD8+ T lymphocytes and suppression of B cell responses
Ting Zhang et al, 2019, Sci. China Life Sci. CrossRef
Dihydroartemisinin initiates ferroptosis in glioblastoma through GPX4 inhibition
Renxin Yi et al, 2020 CrossRef
Dihydroartemisinin Modulates Apoptosis and Autophagy in Multiple Myeloma through the P38/MAPK and Wnt/β-Catenin Signaling Pathways
Xiuhua Wu et al, 2020, Oxidative Medicine and Cellular Longevity CrossRef
Dihydroartemisinin Attenuates Pulmonary Hypertension Through Inhibition of Pulmonary Vascular Remodeling in Rats
Ming Tang et al, 2020 CrossRef
Dihydroartemisinin as a Sensitizing Agent in Cancer Therapies.
Qingrong Li et al, 2021, Onco Targets Ther CrossRef
The multifaceted NF-kB: are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors?
Mariana Medeiros et al, 2021, Cell. Mol. Life Sci. CrossRef
Dihydroartemisinin: A Potential Drug for the Treatment of Malignancies and Inflammatory Diseases
Ran Yu et al, 2021, Front. Oncol. CrossRef
Development of Nanoscale Drug Delivery Systems of Dihydroartemisinin for Cancer Therapy: A Review
Ka Hong Wong et al, 2022, Asian Journal of Pharmaceutical Sciences CrossRef
A Cuproptosis Activation Scoring model predicts neoplasm-immunity interactions and personalized treatments in glioma
Bo Chen et al, 2022, Computers in Biology and Medicine CrossRef
null
Vasiliki Zoi et al, 2023 CrossRef
Dihydroartemisinin inhibits EMT of glioma via gene BASP1 in extrachromosomal DNA
Zhongyou Que et al, 2023, Biochemical and Biophysical Research Communications CrossRef
Dihydroartemisinin suppresses glioma growth by repressing ERRα-mediated mitochondrial biogenesis
Wenxin Zhang et al, 2023, Mol Cell Biochem CrossRef
Dihydroartemisinin, a potential PTGS1 inhibitor, potentiated cisplatin-induced cell death in non-small cell lung cancer through activating ROS-mediated multiple signaling pathways
Lianli Ni et al, 2024, Neoplasia CrossRef